RxDoctor Payments Data

Shadi Idris, MD

Clinical Cardiac Electrophysiology · Kalamazoo, MINPI 1891919312

Payments from drug & device makers

$7,500in general payments, 2019–2025

Across 110 payments — averaging $68.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Medtronic$1K
  • Abbott$902
  • Medical Device Business Services, Inc.$893
  • Biosense Webster, Inc.$237
  • Philips North America LLC$217
  • plus $596 from 12 others

What the payments were for

  • Travel & lodging$2,42932%
  • Food & beverage$5,07268%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,500 in reported general payments places this provider in the 25th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

See all clinical cardiac electrophysiology providers in Michigan

Medicare billing

Part B allowed, 2024
$228,546
Medicare patients
465
Services billed
2,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$214,275
XareltoRivaroxaban36$23,816
EntrestoSacubitril/Valsartan16$21,043
Metoprolol Succinate355$6,841
Amiodarone Hcl184$5,079
ClopidogrelClopidogrel Bisulfate154$3,156
Propafenone Hcl ErPropafenone Hcl11$2,797
Flecainide Acetate51$2,564
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$1,317
Carvedilol62$947
Mexiletine Hcl11$928
Propafenone Hcl17$565
Cartia XtDiltiazem Hcl11$439
Pantoprazole Sodium30$332
Warfarin Sodium28$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$214,275227 claims
NovartisEntresto$36$21,04316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

Other clinical cardiac electrophysiology in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →